Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

Alhossain A. Khalafallah; Bernadene Fernandopulle; Terry Brain

doi:10.4084/mjhid.2010.012

	Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain
DOI: https://doi.org/10.4084/mjhid.2010.012
Alhossain A. Khalafallah Launceston General Hospital, Australia \| alhossain@yahoo.com Bernadene Fernandopulle Launceston General Hospital, Tasmania, Australia Terry Brain Launceston General Hospital, Tasmania, Australia
Abstract No Abstract Available Keywords Intermediate, high-risk MDS; IPSS; lenalidomide; hematological response; dose-modified.
Full Text: PDF HTML
Submitted: 2014-06-11 12:31:25 Published: 2010-05-31 00:00:00 Search for citations in Google Scholar Related articles: Google Scholar